GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Debt-to-Asset

Telo Genomics (Telo Genomics) Debt-to-Asset : 0.02 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Debt-to-Asset?

Telo Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Telo Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil. Telo Genomics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $1.14 Mil. Telo Genomics's debt to asset for the quarter that ended in Dec. 2023 was 0.02.


Telo Genomics Debt-to-Asset Historical Data

The historical data trend for Telo Genomics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Debt-to-Asset Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 0.04 0.01 0.01 0.01

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.04 0.01 0.02 0.02

Competitive Comparison of Telo Genomics's Debt-to-Asset

For the Diagnostics & Research subindustry, Telo Genomics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Debt-to-Asset falls into.



Telo Genomics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Telo Genomics's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Telo Genomics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics  (OTCPK:TDSGF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Telo Genomics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.